Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Kriya forged an antibody discovery agreement with Twist to support the delivery of antibodies with AAV gene therapy in therapeutic oncology applications.
Shares of Adaptive are climbing this morning after the company announced a reorganization of priorities to spur future growth, including a workforce reduction of approximately 12%.
Akari announced that votucalis has potential as a treatment for pain and itch associated with conditions such as atopic dermatitis, psoriasis and neuropathic pain.
DNAnexus announced it has secured $200 million in funding to advance the life sciences industry’s adoption of its platform.
AbbVie and Alvotech have settled a case, granting Alvotech a non-exclusive license to all Humira-related patents in the United States beginning on July 1, 2023.
Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.
Solve FSHD exists to fund biotechnology and biopharmaceutical research and development efforts toward finding a treatment and cure for FSHD.
BioNTech announced an expansion on its collaboration with Regeneron to continue advancing mRNA technology and develop novel treatments for a variety of cancers.
The XTEND-1 study showed that efanesoctocog alfa met its primary endpoint of clinically meaningful bleed prevention in people ages 12 years and older with severe hemophilia.
Venture partnerships won big this week, and genetic therapies-related startups raked in millions. Here’s where the money went.
Before next-generation metabolomics becomes mainstream, the medical establishment needs to expand its mindset around cancer and translate this understanding into the clinic.
From artificial intelligence breakthroughs to at-home genetic testing, here are some ways COVID-19 has changed the biopharma industry and what we may see in the near future.